NAYA Biosciences Files DEF 14A for Executive Compensation
Ticker: IVF · Form: DEF 14A · Filed: Feb 11, 2025 · CIK: 1417926
Sentiment: neutral
Topics: executive-compensation, corporate-governance, filing
TL;DR
NAYA Bio DEF 14A out: exec comp details for FY24. Look at stock/option awards.
AI Summary
NAYA Biosciences, Inc. filed a DEF 14A on February 11, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 2024. The filing includes information on stock awards, option awards, and fair value adjustments to total compensation for key personnel. NAYA Biosciences, formerly INVO Bioscience, Inc., is incorporated in Nevada and operates in the surgical and medical instruments sector.
Why It Matters
This filing provides transparency into how NAYA Biosciences compensates its top executives, which can influence investor decisions and perceptions of the company's financial health and management strategy.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but they can reveal information about executive compensation and potential shareholder concerns that might impact stock price.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation details.)
- 2023 — Fiscal Year (Previous fiscal year for comparative compensation data.)
- 2022 — Fiscal Year (Earlier fiscal year for comparative compensation data.)
Key Players & Entities
- NAYA Biosciences, Inc. (company) — Filer
- INVO Bioscience, Inc. (company) — Former company name
- EMY'S SALSA AJI DISTRIBUTION COMPANY, INC. (company) — Former company name
- 20250211 (date) — Filing date
- 2024-12-31 (date) — Fiscal year end
- 3841 (number) — Standard Industrial Classification (SIC) code for Surgical & Medical Instruments & Apparatus
FAQ
What were the total compensation figures for NAYA Biosciences' named executive officers in fiscal year 2024?
The filing indicates compensation details for fiscal years 2024, 2023, and 2022, including stock awards, option awards, and fair value adjustments, but specific dollar amounts for named executive officers are not detailed in the provided excerpt.
What is the primary business of NAYA Biosciences, Inc. according to the SIC code?
NAYA Biosciences, Inc. is classified under SIC code 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
When did NAYA Biosciences, Inc. change its name from INVO Bioscience, Inc.?
The company formerly known as INVO Bioscience, Inc. changed its name on January 6, 2009.
What is the filing date of this DEF 14A?
This DEF 14A filing was made on February 11, 2025.
Where is NAYA Biosciences, Inc. incorporated?
NAYA Biosciences, Inc. is incorporated in Nevada (NV).
Filing Stats: 4,959 words · 20 min read · ~17 pages · Grade level 11.4 · Accepted 2025-02-11 14:58:41
Key Financial Figures
- $3,934,146 — e Debenture in the principal balance of $3,934,146 due December 11, 2025 (the "Debenture")
Filing Documents
- formdef14a.htm (DEF 14A) — 2412KB
- formpre14a_001.jpg (GRAPHIC) — 8KB
- formpre14a_002.jpg (GRAPHIC) — 32KB
- formpre14a_003.jpg (GRAPHIC) — 38KB
- formpre14a_004.jpg (GRAPHIC) — 24KB
- formpre14a_005.jpg (GRAPHIC) — 39KB
- formpre14a_006.jpg (GRAPHIC) — 64KB
- formpre14a_007.jpg (GRAPHIC) — 41KB
- annexf_001.jpg (GRAPHIC) — 632KB
- annexf_002.jpg (GRAPHIC) — 456KB
- 0001493152-25-005874.txt ( ) — 6801KB
- naya-20241231.xsd (EX-101.SCH) — 5KB
- naya-20241231_def.xml (EX-101.DEF) — 10KB
- naya-20241231_lab.xml (EX-101.LAB) — 63KB
- naya-20241231_pre.xml (EX-101.PRE) — 44KB
- formdef14a_htm.xml (XML) — 113KB
FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY
FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY 22
RISK FACTORS
RISK FACTORS 24 DESCRIPTION OF BUSINESS 100 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION OF NAYA THERAPEUTICS, INC. (FORMER NAME NAYA BIOSCIENCES, INC.) 118 MATTERS TO BE VOTED ON 129 BOARD OF DIRECTORS AND CORPORATE GOVERNANCE 150 EXECUTIVE AND DIRECTOR COMPENSATION 153 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 162
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 163
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 169 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 170 OTHER MATTERS 171 ANNEX A: AUDITED CONSOLIDATED FINANCIAL STATEMENTS OF NAYA THERAPEUTICS, INC. (FORMER NAME NAYA BIOSCIENCES, INC.) (YEARS ENDED DECEMBER 31, 2023 AND 2022) A-1 ANNEX B: UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF NAYA THERAPEUTICS, INC. (FORMER NAME NAYA BIOSCIENCES, INC.) (NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023) B-1 ANNEX C: UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION C-1 ANNEX D: AMENDMENT TO THE SECOND AMENDED AND RESTATED 2019 STOCK INCENTIVE PLAN D-1 ANNEX E: SECOND AMENDED AND RESTATED 2019 STOCK INCENTIVE PLAN E-1 ANNEX F: CERTIFICATE OF AMENDMENT TO RESTATED ARTICLES OF INCORPORATION F-1 i 5582 Broadcast Court Sarasota, Florida 34240 (978) 878-9505 PROXY 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held Virtually on March 10, 2025 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Q. Why did I receive these proxy materials? A. We are sending you these proxy materials because our Board is soliciting your proxy to vote at the Annual Meeting. You are invited to attend the Annual Meeting virtually via the Internet to vote on the proposals described in this proxy statement. However, you do not need to attend the Annual Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or follow the instructions below to submit your proxy by phone or online. We intend to begin mailing this proxy statement, the attached notice of Annual Meeting, and the enclosed proxy card, on or about February 13, 2025 to all shareholders of record entitled to vote at the Annual Meeting. Only shareholders who owned our common stock on January 24, 2025 are entitled to vote at the Annual Meeting. Q. How do I attend the Annual Meeting? A. The Annual Meeting will be held on March 10, 2025 at 12:00 p